Newsquawk Logo

US BROKER MOVES: SPOT upgraded at Rosenblatt; BF.B downgraded at JPM

The recent analyst upgrades for Centene (CNC), Spotify (SPOT), and T-Mobile (TMUS) suggest positive sentiment in health care, tech, and telecom sectors, likely driven by strong outlooks.

Newsquawk StaffPublished On the live feed at — 4 more headlines followed before this page went public
Newsquawk headlinesUTC

AbbVie Inc. (ABBV) Q1 2026 (USD): Adj. EPS 2.65 (exp. 2.59), Revenue 15bln (exp. 14.72bln). FY Adj. EPS view 14.08-14.28 (exp. 14.12)

US PRE-MARKET MOVERS: BE, NXPI, STX, V, GD, ADP, SBUX, BG, TMUS, MDLZ, HUM, BKNG, GEHC, HOOD

US BROKER MOVES: SPOT upgraded at Rosenblatt; BF.B downgraded at JPM

GSK (GSK LN) are expecting three times yearly Cabenuva launch in 2028 with phase three study on track and also anticipates new standard of care that doubles provider administration capacity while highly desired by patients and physicians

Russia could increase seaborne crude exports in May as port capacity has been restored and weather will improve, according to sources

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.

UPGRADES

  • Centene (CNC) Upgraded to Overweight at Cantor; PT USD 60
  • Crane Co. (CR) Upgraded to Buy at Stifel; PT USD 215
  • Elevance (ELV) Upgraded to Buy at BofA; PT USD 435
  • Franklin Resources (BEN) Upgraded to Equal-Weight at Barclays; PT USD 31
  • MaxLinear (MXL) Upgraded to Buy at Loop Capital; PT USD 75
  • NeoGenomics (NEO) Upgraded to Buy at Benchmark; PT USD 11
  • NeoGenomics (NEO) Upgraded to Outperform at Leerink; PT USD 25
  • Qiagen (QGEN) Upgraded to Outperform at Baird; PT USD 43
  • Radian (RDN) Upgraded to Buy at BofA
  • Spotify (SPOT) Upgraded to Buy at Rosenblatt Securities Inc; PT USD 500
  • Spotify (SPOT) Upgraded to Buy at Inderes; PT USD 570
  • T-Mobile (TMUS) Upgraded to Outperform at Oppenheimer; PT USD 260
  • Tamboran Resources (TBN) Upgraded to Outperform at RBC; PT USD 55
  • Zeta (ZETA) Upgraded to Overweight at KeyBanc

DOWNGRADES

  • Boston Scientific (BSX) Downgraded to Neutral at Daiwa; PT USD 60
  • Brown-Forman (BF/B) Downgraded to Underweight at JPMorgan; PT USD 23
  • Clearwater Paper (CLW) Downgraded to Hold at TD Cowen; PT USD 17
  • MercadoLibre (MELI) Downgraded to Neutral at UBS; PT USD 2,050
  • Purple Innovation (PRPL) Downgraded to Sector Weight at KeyBanc
  • Qualys (QLYS) Downgraded to Market Perform at William Blair
  • Rapid7 (RPD) Downgraded to Market Perform at William Blair
  • StoneCo (STNE) Downgraded to Neutral at Goldman; PT USD 14
  • Sysco (SYY) Downgraded to Hold at Deutsche Bank; PT USD 84
  • Tenable (TENB) Downgraded to Market Perform at William Blair
  • Universal Health (UHS) Downgraded to Market Perform at Raymond James

INITIATIONS

  • Aktis Oncology (AKTS) Initiated at New Outperform at William Blair
  • Alibaba (BABA) ADRs Initiated at New Outperform at BNP Paribas; PT USD 209
  • Corbus Pharmaceuticals (CRBP) Initiated at New Buy at Guggenheim; PT USD 45
  • Hennessy Capital Investment Corp. VII (HVIIU) Initiated at New Buy at Benchmark
  • Legence (LGN) Initiated at New Buy at Loop Capital
  • Nvidia (NVDA) Initiated at New Outperform at Safra; PT USD 300
  • PicS (PICS) Initiated at New Buy at Banco BTG Pactual; PT USD 20
Context

Conversely, the downgrades for Brown-Forman (BF.B) and Boston Scientific (BSX) indicate concerns about their near-term performance, which could weigh on their stock prices. Overall, these adjustments may lead to sector rotations, impacting related stocks and market sentiment.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.